Sanofi (NASDAQ:SNY) Shares Sold by Alan B Lancz & Associates Inc.

Alan B Lancz & Associates Inc. trimmed its holdings in shares of Sanofi (NASDAQ:SNY) by 4.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,050 shares of the company’s stock after selling 250 shares during the period. Alan B Lancz & Associates Inc.’s holdings in Sanofi were worth $349,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in SNY. Boston Partners boosted its holdings in shares of Sanofi by 0.3% in the 1st quarter. Boston Partners now owns 13,066,403 shares of the company’s stock valued at $635,280,000 after buying an additional 33,657 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Sanofi by 19.0% in the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after acquiring an additional 1,370,232 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC boosted its stake in Sanofi by 113.8% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after acquiring an additional 3,164,092 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in shares of Sanofi by 8.2% during the second quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock worth $157,803,000 after purchasing an additional 246,224 shares during the last quarter. Finally, Federated Hermes Inc. increased its position in shares of Sanofi by 26.5% during the second quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock worth $155,950,000 after purchasing an additional 673,172 shares in the last quarter. 10.04% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

SNY has been the subject of a number of research analyst reports. Citigroup raised Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Argus boosted their price objective on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Finally, StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Price Performance

Shares of SNY opened at $51.32 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. Sanofi has a fifty-two week low of $45.13 and a fifty-two week high of $58.97. The firm has a 50-day simple moving average of $55.49 and a 200-day simple moving average of $52.20. The company has a market capitalization of $130.24 billion, a price-to-earnings ratio of 26.18, a price-to-earnings-growth ratio of 1.31 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. The company had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same period last year, the firm earned $2.55 EPS. On average, equities research analysts anticipate that Sanofi will post 4.27 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.